A tighter archive for life-science signals.
Search once, then narrow by source or topic.
Catalent plans to close Belgium cell therapy site
Catalent plans to close Belgium cell therapy site
Sarepta touts three-year Duchenne gene therapy data after patient deaths
Sarepta touts three-year Duchenne gene therapy data after patient deaths
Genyro licences DNA builder from Caltech; Dizal targets Hong Kong listing
Genyro licences DNA builder from Caltech; Dizal targets Hong Kong listing
UK medicines agency seized 20M illegal drugs last year, including GLP-1s
UK medicines agency seized 20M illegal drugs last year, including GLP-1s
Genmab halts enrollment for cancer drug from ProfoundBio buyout
Genmab halts enrollment for cancer drug from ProfoundBio buyout
First-movers respond to herding; BioMarin vets start new biotech; GSK buys RAPT Therapeutics; and more
First-movers respond to herding; BioMarin vets start new biotech; GSK buys RAPT Therapeutics; and more
Novo's Wegovy pill off to a solid start after just two weeks on market
Novo's Wegovy pill off to a solid start after just two weeks on market
EU kicks off one-year pilot to expedite multinational trials
EU kicks off one-year pilot to expedite multinational trials
ACIP members depict diverging goals after schedule change
ACIP members depict diverging goals after schedule change
F2G CEO outlines biotech's FDA resubmission plans, funding and expansion
F2G CEO outlines biotech's FDA resubmission plans, funding and expansion
Sanofi's Phase 3 eczema data cloud hopes for potential immunology blockbuster
Sanofi's Phase 3 eczema data cloud hopes for potential immunology blockbuster
Lilly was the only pharma bidder for Ventyx
Lilly was the only pharma bidder for Ventyx
Insurance CEOs defend their businesses at House hearing
Insurance CEOs defend their businesses at House hearing
Former FDA deputies land at Lilly, AbbVie; Italy's Angelini has a new CEO
Former FDA deputies land at Lilly, AbbVie; Italy's Angelini has a new CEO
High court picked Hikma’s ‘skinny label’ fight after letting the issue ‘percolate’
High court picked Hikma’s ‘skinny label’ fight after letting the issue ‘percolate’
Drugmakers spent less on Washington lobbying in 2025's final quarter
Drugmakers spent less on Washington lobbying in 2025's final quarter
Corcept's drug extends patients' lives in key ovarian cancer study
Corcept's drug extends patients' lives in key ovarian cancer study
China-founded pharma Corxel raises up to $287M for oral GLP-1
China-founded pharma Corxel raises up to $287M for oral GLP-1
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page